Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
V. Demichev,
P. Tober-Lau,
O. Lemke,
T. Nazarenko,
C. Thibeault,
H. Whitwell,
A. Röhl,
A. Freiwald,
L. Szyrwiel,
D. Ludwig,
E. Helbig,
P. Stubbemann,
L. Lippert,
S. Klein,
M. Mittermaier,
F. Machleidt,
C. V. García,
C. Ruwwe-Glösenkamp,
T. Lingscheid,
M. S. Stegemann,
P. Enghard,
A. Uhrig,
H. C. Müller-Redetzky,
S. Hippenstiel,
M. Witzenrath,
N. Suttorp,
M. Mülleder,
L. E. Sander,
P. group,
M. Ralser,
F. Kurth,
C. Correia-Melo,
S. Aulakh,
N. Grüning,
O. Blyuss,
S. Vernardis,
M. White,
C. Messner,
M. Joannidis,
T. Sonnweber,
A. Pizzini,
Y. Wohlfarter,
S. Sahanic,
R. Hilbe,
B. Schaefer,
S. Wagner,
L. Bosquillon de Jarcy,
M. Pfeiffer,
L. Jürgens,
S. Denker,
D. Zickler,
A. Zelezniak,
A. Campbell,
C. Hayward,
D. Porteous,
R. Marioni,
H. Zoller,
J. Löffler-Ragg,
M. Keller,
I. Tancevski,
J. Timms,
A. Zaikin,
M. Ramharter and
K. Lilley,
"A time-resolved proteomic and prognostic map of COVID-19",
Cell Syst. 2021;12(8):780-794.e7,
2021.
V. Demichev and
et al,
"A time-resolved proteomic and prognostic map of COVID-19",
Cell Systems,
2021.
| DOI: | 10.1016/j.cels.2021.05.005 |
L. Brümmer,
S. Katzenschlager,
M. Gaeddert and
D. Stahl,
"Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis",
PLOS Medicine,
vol. 18,
no. 8,
2021.
| DOI: | 10.1371/journal.pmed.1003735 |
| Datei: | https://doi.org/10.1371/journal.pmed.1003735 |
M. L. Stanifer and
S. Boulant,
"Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 (BSL-3) Conditions",
JoVE,
no. 166,
pp. e62857,
2021.
| DOI: | 10.3791/62857 |
D. Mürbe,
M. Kriegel,
J. Lange and
et al,
"Aerosol emission in professional singing of classical music",
Sci Rep,
vol. 11,
2021.
| DOI: | 10.1038/s41598-021-93281-x |
D. Mürbe,
M. Kriegel,
J. Lange and
et al,
"Aerosol emission of adolescents voices during speaking, singing and shouting",
PLoS ONE,
vol. 16,
no. 2,
2021.
| DOI: | 10.1371/journal.pone.0246819 |
J. Schwartz,
M. C. Reuters,
M. Schallenburger and
D. Stahl,
"Allgemeine Palliativversorgung in Pandemiezeiten",
Onkologe,
vol. 27,
pp. 686-690,
2021.
| DOI: | 10.1007/s00761-021-00970-3 |
J. P. Weber,
J. M. Tielker,
N. Kamandi and
et al,
"Ambulante Betreuung onkologischer Patienten in palliativer Behandlungssituation und ihrer Angehörigen in der COVID-19-Pandemie",
Onkologe,
vol. 27,
pp. 783-789,
2021.
| DOI: | 10.1007/s00761-021-00974-z |
V. Priesemann,
R. Balling,
M. M. Brinkmann,
S. Ciesek,
T. Czypionka,
I. Eckerle,
G. Giordano,
C. Hanson,
Z. Hel,
P. Hotulainen,
P. Klimek,
A. Nassehi,
A. Peichl,
M. Perc,
E. Petelos,
B. Prainsack and
E. Szczurek,
"An action plan for pan-European defence against new SARS-CoV-2 variants",
The Lancet,
vol. 397,
no. 10273,
pp. 469—470,
2021.
| DOI: | 10.1016/S0140-6736(21)00150-1 |
G. Bagheri,
B. Thiede,
B. Hejazi and
et al,
"An upper bound on one-to-one exposure to infectious human respiratory particles",
PNAS,
vol. 118,
no. 49,
2021.
| DOI: | 10.1073/pnas.2110117118 |
J. Schulze,
C. Mache,
A. Balazs,
D. Frey,
D. Niemeyer and
e. a. Olze,
"Analysis of SARS-CoV-2 replication in explant cultures of the human upper respiratory tract reveals broad tissue tropism of wild-type and B.1.1.7 variant viruses",
J Infect Dis,
2021.
| DOI: | 10.1093/infdis/jiab489 |
M. Renn,
E. Bartok,
T. Zillinger,
G. Hartmann and
R. Behrendt,
"Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions",
Pharmacology & Therapeutics,
pp. 107931,
2021.
| DOI: | 10.1016/j.pharmthera.2021.107931 |
D. Gagiannis,
V. G. Umathum,
W. Bloch,
C. Rother,
M. Stahl,
H. M. Witte,
S. Djudjaj,
P. Boor and
K. Steinestel,
"Antemortem vs Postmortem Histopathologic and Ultrastructural Findings in Paired Transbronchial Biopsy Specimens and Lung Autopsy Samples From Three Patients With Confirmed SARS-CoV-2",
Am J Clin Pathol,
2021.
| DOI: | 10.1093/ajcp/aqab087 |
O. Nikolai,
C. Rohardt,
F. Tobian and
et al,
"Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter?",
Infect Dis,
vol. 53,
no. 12,
2021.
| DOI: | 10.1080/23744235.2021.1969426 |
| Datei: | https://doi.org/10.1080/23744235.2021.1969426 |
M. Popp,
M. Stegemann,
M. Riemer,
M. Metzendorf,
C. S. Romero,
A. Mikolajewska,
P. Kranke,
P. Meybohm,
N. Skoetz and
S. Weibel,
"Antibiotics for the treatment of COVID‐19",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD015025,
2021.
| DOI: | 10.1002/14651858.CD015025 |
P. Möller,
G. Uzun,
A. Singh,
A. Beck,
M. Bettag,
H. Bösmüller,
M. Guthoff,
F. Dorn,
G. C. Petzold,
H. Henkes,
N. Heyne,
H. Jumaa,
K. Kreiser,
C. Limpach,
B. Luz,
M. Maschke,
J. Müller,
J. Münch,
S. Nagel,
B. Pötzsch,
J. Müller,
C. Schlegel,
A. Viardot,
H. Bäzner,
M. Wolf,
L. Pelzl,
V. Warm,
W. A. Willinek,
J. Steiner,
N. Schneiderhan-Marra,
D. Vollherbst,
U. J. Sachs,
F. Fend and
T. Bakchoul,
"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia",
Haematologica,
vol. 106,
no. 8,
pp. 2170-2179,
Aug.
2021.
| DOI: | 10.3324/haematol.2021.279000 |
T. Aschman,
J. Schneider,
S. Greuel,
J. Meinhardt,
S. Streit,
H. Goebel,
I. Büttnerova,
S. Elezkurtaj,
F. Scheibe,
J. Radke,
C. Meisel,
C. Drosten,
H. Radbruch,
F. Heppner,
V. Corman and
W. Stenzel,
"Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died",
JAMA Neurol,
vol. 78,
no. 8,
pp. 948-960,
Aug.
2021.
| DOI: | 10.1001/jamaneurol.2021.2004 |
T. Aschman,
J. Schneider,
S. Greuel,
J. Meinhardt,
S. Streit and
e. a. Goebel,
"Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died",
JAMA Neurol,
vol. 78,
pp. 948—960,
2021.
O. Pogarell,
L. Pröbstl,
M. Rüb,
H. F. Wiegand,
O. Tüscher,
K. Lieb,
E. Wassiliwizky,
G. Gerlinger,
A. Heinz and
P. Falkai,
"Auswirkungen der COVID-19-Pandemie auf die Versorgungssituation in psychiatrischen Kliniken in Deutschland",
Der Nervenarzt,
vol. 92,
no. 6,
pp. 562—570,
2021.
| DOI: | 10.1007/s00115-021-01129-6 |
J. Klüpfel,
R. C. Koros,
K. Dehne and
et al,
"Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA)",
Anal Bioanal Chem,
vol. 413,
no. 22,
2021.
| DOI: | 10.1007/s00216-021-03315-6 |
K. Evert,
T. Dienemann,
C. Brochhausen,
D. Lunz,
M. Lubnow,
M. Ritzka,
F. Keil,
M. Trummer,
A. Scheiter,
B. Salzberger and
D. Stahl,
"Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation",
Virchows Arch,
pp. 1-12,
2021.
| DOI: | 10.1007/s00428-020-03014-0 |
P. Arora and
et al,
"B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination",
Cell Reports,
pp. 109825,
2021.
| DOI: | 10.1016/j.celrep.2021.109825 |
C. Bartenschlager,
C. Römmele and
S. Temizel,
"Befragung zum Besuchsmanagement: Wie Pflegeeinrichtungen Besuche während der COVID-19-Pandemie organisierten. Protzenziale digitaler Systeme kaum genutzt",
CAREkonkret,
vol. 32/33,
2021.
| Datei: | https://opus.bibliothek.uni-augsburg.de/opus4/88555 |
S. Kumar,
D. Çalışkan,
J. Janowski,
A. Faist,
B. Conrad and
e. a. Lange,
"Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics",
Front Immunol,
vol. 12,
pp. 752227,
2021.
S. Traxler,
M. Schindler,
H. Bösmüller and
K. Klingel,
"Biologie und Pathologie von Coronaviren [Biology and pathology of coronaviruses]",
Pathologe,
vol. 42,
no. 2,
pp. 149-154,
2021.
J. Swoboda,
D. Wittschieber,
J. Sanft,
S. Kleemann,
S. Elschner,
H. Ihle,
M. Hubig,
M. Pletz,
G. Mall and
N. Gassler,
"Bone marrow haemophagocytosis indicates severe infection with severe acute respiratory syndrome coronavirus 2",
Histopathology,
vol. 78,
no. 5,
pp. 727-737,
Apr.
2021.
| DOI: | 10.1111/his.14281 |
J. Burns,
A. Movsisyan,
E. Rehfuess and
J. Stratil,
"Border control and SARS-CoV-2: an opportunity for generating highly policy-relevant, real-world evidence",
Journal of Travel Medicine,
pp. 1—3,
2021.
| DOI: | 10.1093/jtm/taab037 |
V. Priesemann,
M. M. Brinkmann,
S. Ciesek,
S. Cuschieri,
T. Czypionka,
G. Giordano,
C. Hanson,
N. Hens,
E. Iftekhar,
P. Klimek,
M. Kretzschmar,
A. Peichl,
M. Perc,
F. Sannino,
E. Schernhammer,
A. Schmidt,
A. Staines and
E. Szczurek,
"Call for a pan-European COVID-19 response must be comprehensive – Authors‘ reply",
The Lancet,
vol. 397,
no. 10284,
pp. 1541,
2021.
| DOI: | 10.1016/S0140-6736(21)00462-1 |
V. Priesemann,
M. M. Brinkmann,
S. Ciesek,
S. Cuschieri,
T. Czypionka,
G. Giordano,
D. Gurdasani,
C. Hanson,
N. Hens,
E. Iftekhar,
M. Kelly-Irving,
P. Klimek,
M. Kretzschmar,
A. Peichl,
M. Perc,
F. Sannino,
E. Schernhammer,
A. Schmidt,
A. Staines and
E. Szczurek,
"Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections",
The Lancet,
vol. 397,
no. 10269,
pp. 92—93,
2021.
| DOI: | 10.1016/S0140-6736(20)32625-8 |
H. Bräuninger,
B. Stoffers,
A. Fitzek and
et al,
"Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart",
Cardiovasc Res,
pp. cvab322,
2021.
| DOI: | 10.1093/cvr/cvab322 |
J. Doehn,
C. Tabeling,
R. Biesen,
J. Saccomanno,
E. Madlung,
E. Pappe,
F. Gabriel,
F. Kurth,
C. Meisel,
V. Corman and
D. Stahl,
"CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity",
Infection,
vol. 49,
no. 4,
pp. 757—762,
2021.
| DOI: | 10.1007/s15010-021-01606-9 |
J. Doehn,
C. Tabeling,
R. Biesen,
J. Saccomanno,
E. Madlung,
E. Pappe,
F. Gabriel,
F. Kurth,
C. Meisel,
V. M. Corman,
L. G. Hanitsch,
S. Treskatsch,
K. Heim,
M. S. Stegemann,
C. Ruwwe-Glösenkamp,
H. C. Müller-Redetzky,
A. Uhrig,
R. Somasundaram,
C. Spies,
H. Bernuth,
J. Hofmann,
C. Drosten,
N. Suttorp,
M. Witzenrath,
L. E. Sander and
R. Hübner,
"CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.",
Infection.2021;49(4):757-762,
2021.
B. Lorenz-Depiereux,
J. J. Vehreschild,
M. Stecher,
L. Pilgram,
M. Witzenrath,
C. Pley,
C. Thibeault,
S. Schreiber,
T. Bahmer,
L. Fiedler-Lacombe,
A. Blumentritt,
M. Stahl,
W. Hoffmann,
S. Hanß,
D. Krefting,
C. Schäfer,
M. Nauck,
J. Schaller,
M. Hoffmann,
M. Kraus and
On Behalf Of The Napkon Study Group,
"Challenges for Ethics coordination in a large Cohort Network – experiences in the German National Pandemic Cohort Network NAPKON.",
Kongress European Biobank Week 2021,
2021.
A. Walker,
T. Houwaart,
P. Finzer and
et al,
"Characterization of SARS-CoV-2 genetic structure and infection clusters in a large German city based on integrated genomic surveillance, outbreak analysis, and contact tracing",
Epidemiology,
2021.
| DOI: | 10.1101/2021.02.13.21251678 |
| Datei: | https://doi.org/10.1101/2021.02.13.21251678 |
A. Walker,
T. Houwaart,
P. Finzer and
et al,
"Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection clusters based on integrated genomic surveillance, outbreak analysis and contact tracing in an urban setting",
Clin Infect Dis,
vol. 74,
no. 6,
2021.
| DOI: | 10.1093/cid/ciab588 |
J. Ankerhold,
S. Giese,
P. Kolb and
et al,
"Circulating multimeric immune complexes drive immunopathology in COVID-19",
Immunology,
2021.
| DOI: | 10.1101/2021.06.25.449893 |
C. Thibeault,
B. Mühlemann,
E. Helbig,
M. Mittermaier,
T. Lingscheid,
P. Tober-Lau,
L. Meyer-Arndt,
L. Meiners,
P. Stubbemann,
S. Haenel and
D. Stahl,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
vol. 49,
no. 4,
pp. 703—714,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
C. Thibeault and
et al,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
A. Mikolajewska,
A. Fischer,
V. Piechotta,
A. Mueller,
M. Metzendorf,
M. Becker,
E. Dorando,
R. L. Pacheco,
A. L. C. Martimbianco,
R. Riera,
N. Skoetz and
M. Stegemann,
"Colchicine for the treatment of COVID‐19",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD015045,
2021.
| DOI: | 10.1002/14651858.CD015045 |
M. Ochs,
S. Timm,
S. Elezkurtaj,
D. Horst,
J. Meinhardt and
e. a. Heppner,
"Collapse induration of alveoli is an ultrastructural finding in a COVID-19 patient",
Eur Respir J,
vol. 57,
2021.
| DOI: | 10.1183/13993003.02311-2020 |
K. Herbst,
M. Meurer,
D. Kirrmaier and
D. Stahl,
"Colorimetric RT-LAMP and LAMP-sequencing for Detecting SARS-CoV-2 RNA in Clinical Samples",
BIO-Protocols,
vol. 11,
no. 6,
2021.
| DOI: | 10.21769/BioProtoc.3964 |
| Datei: | https://doi.org/10.21769/BioProtoc.3964 |
L. Brunotte,
S. Zheng,
A. Mecate-Zambrano,
J. Tang,
S. Ludwig and
e. a. Rescher,
"Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro",
Pharmaceutics,
vol. 13,
2021.
A. Müller,
F. Engler,
D. Schütze,
P. Nohl-Deryk and
C. Güthlin,
"Communication experience by secure instant messaging during the Covid-19 pandemic for general practitioners and public health workers – a qualitative analysis",
Doc21dkvf051,
2021.
| DOI: | 10.3205/21dkvf051 |
A. Osterman,
M. Iglhaut,
A. Lehner and
et al,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Med Microbiol Immunol,
vol. 210,
2021.
| DOI: | 10.1007/s00430-021-00719-0 |
A. Osterman,
M. Iglhaut,
A. Lehner,
P. Späth,
M. Stern,
H. Autenrieth,
M. Muenchhoff,
A. Graf,
S. Krebs,
H. Blum,
A. Baiker,
N. Grzimek-Koschewa,
U. Protzer,
L. Kaderali,
H. Baldauf and
O. T. Keppler,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Medical microbiology and immunology,
vol. 210,
no. 5-6,
pp. 263—275,
2021.
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
| DOI: | 10.1007/s00430-021-00719-0 |
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
P. Georg and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
P. Georg,
R. Astaburuaga-García,
L. Bonaguro and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
B. Föh,
M. Borsche,
A. Balck and
et al,
"Complications of nasal and pharyngeal swabs – a relevant challenge of the COVID-19 pandemic?",
Eur Respir J,
2021.
| DOI: | 10.1183/13993003.04004-2020 |
V. Piechotta,
C. Iannizzi,
K. L. Chai,
S. J. Valk,
C. Kimber,
E. Dorando,
I. Monsef,
E. M. Wood,
A. A. Lamikanra,
D. J. Roberts,
Z. McQuilten,
C. So-Osman,
L. J. Estcourt and
N. Skoetz,
"Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD013600,
2021.
| DOI: | 10.1002/14651858.CD013600.pub4 |
F. Beierle and
et al,
"Corona Health—A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic",
Int J Environ Res Public Health,
vol. 18,
pp. 7395,
2021.
| DOI: | 10.3390/ijerph18147395 |